• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过可扩展的化学分析合理发现分子胶降解剂。

Rational discovery of molecular glue degraders via scalable chemical profiling.

机构信息

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

FMI Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

出版信息

Nat Chem Biol. 2020 Nov;16(11):1199-1207. doi: 10.1038/s41589-020-0594-x. Epub 2020 Aug 3.

DOI:10.1038/s41589-020-0594-x
PMID:32747809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7116640/
Abstract

Targeted protein degradation is a new therapeutic modality based on drugs that destabilize proteins by inducing their proximity to E3 ubiquitin ligases. Of particular interest are molecular glues that can degrade otherwise unligandable proteins by orchestrating direct interactions between target and ligase. However, their discovery has so far been serendipitous, thus hampering broad translational efforts. Here, we describe a scalable strategy toward glue degrader discovery that is based on chemical screening in hyponeddylated cells coupled to a multi-omics target deconvolution campaign. This approach led us to identify compounds that induce ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. Notably, this interaction is independent of a dedicated substrate receptor, thus functionally segregating this mechanism from all described degraders. Collectively, our data outline a versatile and broadly applicable strategy to identify degraders with nonobvious mechanisms and thus empower future drug discovery efforts.

摘要

靶向蛋白降解是一种新的治疗模式,基于通过诱导蛋白质接近 E3 泛素连接酶来使蛋白质不稳定的药物。特别有趣的是分子胶,它可以通过协调靶蛋白和连接酶之间的直接相互作用,来降解原本不可配体的蛋白质。然而,到目前为止,它们的发现都是偶然的,因此阻碍了广泛的转化努力。在这里,我们描述了一种基于在低泛素化细胞中进行化学筛选,结合多组学目标解析的大规模胶降解剂发现策略。这种方法使我们发现了能够通过促使 CDK12- cyclin K 与 CRL4B 连接酶复合物相互作用来诱导 cyclin K 泛素化和降解的化合物。值得注意的是,这种相互作用不依赖于专门的底物受体,因此将这种机制与所有描述的降解剂功能上区分开来。总的来说,我们的数据概述了一种通用且广泛适用的策略,用于鉴定具有不明显机制的降解剂,从而为未来的药物发现提供支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/528a6ca8d5c2/EMS110169-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/69e7022f19d1/EMS110169-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/00849fb07287/EMS110169-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/545564dfc47b/EMS110169-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c7587898fe67/EMS110169-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c98bea582efe/EMS110169-f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/55a8847b61fb/EMS110169-f010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/aee31727bb6c/EMS110169-f011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/2a141ef7e69f/EMS110169-f012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/6d350d7bb2d3/EMS110169-f013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/41f89bdd9234/EMS110169-f014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c01bfa1f4e77/EMS110169-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/8ab38608f9f3/EMS110169-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/f9e43df97278/EMS110169-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/528a6ca8d5c2/EMS110169-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/69e7022f19d1/EMS110169-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/00849fb07287/EMS110169-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/545564dfc47b/EMS110169-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c7587898fe67/EMS110169-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c98bea582efe/EMS110169-f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/55a8847b61fb/EMS110169-f010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/aee31727bb6c/EMS110169-f011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/2a141ef7e69f/EMS110169-f012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/6d350d7bb2d3/EMS110169-f013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/41f89bdd9234/EMS110169-f014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/c01bfa1f4e77/EMS110169-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/8ab38608f9f3/EMS110169-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/f9e43df97278/EMS110169-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8605/7116640/528a6ca8d5c2/EMS110169-f004.jpg

相似文献

1
Rational discovery of molecular glue degraders via scalable chemical profiling.通过可扩展的化学分析合理发现分子胶降解剂。
Nat Chem Biol. 2020 Nov;16(11):1199-1207. doi: 10.1038/s41589-020-0594-x. Epub 2020 Aug 3.
2
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.CDK 抑制剂 CR8 作为一种分子胶降解剂,可使细胞周期蛋白 K 耗竭。
Nature. 2020 Sep;585(7824):293-297. doi: 10.1038/s41586-020-2374-x. Epub 2020 Jun 3.
3
Haven't got a glue: Protein surface variation for the design of molecular glue degraders.毫无头绪:用于设计分子胶降解剂的蛋白质表面变异性。
Cell Chem Biol. 2021 Jul 15;28(7):1032-1047. doi: 10.1016/j.chembiol.2021.04.009. Epub 2021 Apr 29.
4
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches.通过多组学方法鉴定和选择性分析小分子降解剂。
Cell Chem Biol. 2021 Jul 15;28(7):1048-1060. doi: 10.1016/j.chembiol.2021.03.007. Epub 2021 Apr 2.
5
Design principles for cyclin K molecular glue degraders.周期蛋白 K 分子胶降解剂的设计原则。
Nat Chem Biol. 2024 Jan;20(1):93-102. doi: 10.1038/s41589-023-01409-z. Epub 2023 Sep 7.
6
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs.从靶向蛋白降解中推断出其他邻近诱导药物的经验。
ACS Chem Biol. 2024 Oct 18;19(10):2089-2102. doi: 10.1021/acschembio.4c00191. Epub 2024 Sep 12.
7
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance.通过动态追踪底物受体丰度进行 E3 特异性降解剂发现。
J Am Chem Soc. 2023 Jan 18;145(2):1176-1184. doi: 10.1021/jacs.2c10784. Epub 2023 Jan 5.
8
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
9
Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.超越PROTAC的小分子降解剂——挑战与机遇
SLAS Discov. 2021 Apr;26(4):524-533. doi: 10.1177/2472555221991104. Epub 2021 Feb 25.
10
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.发现一种分子胶促进 CDK12-DDB1 相互作用,从而触发细胞周期蛋白 K 的降解。
Elife. 2020 Aug 17;9:e59994. doi: 10.7554/eLife.59994.

引用本文的文献

1
Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.利用细胞周期蛋白和细胞周期蛋白依赖性激酶的靶向降解进行癌症治疗:综述
J Zhejiang Univ Sci B. 2025 Aug 25;26(8):713-739. doi: 10.1631/jzus.B2500021.
2
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics.通过高通量蛋白质组学对cereblon新底物图谱进行无偏映射。
Nat Commun. 2025 Aug 20;16(1):7773. doi: 10.1038/s41467-025-62829-0.
3
Elaboration of molecular glues that target TRIM21 into TRIMTACs that degrade protein aggregates.开发将TRIM21靶向到能降解蛋白质聚集体的TRIMTACs中的分子胶。
Nat Commun. 2025 Jul 16;16(1):6548. doi: 10.1038/s41467-025-61818-7.
4
Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron.超越G环:CRBN分子胶通过一种新型SH3 RT环降解子有效靶向VAV1。
bioRxiv. 2025 Jun 9:2025.06.08.658535. doi: 10.1101/2025.06.08.658535.
5
The changing landscape of medicinal chemistry optimization.药物化学优化的不断变化的格局。
Nat Rev Drug Discov. 2025 Jul 7. doi: 10.1038/s41573-025-01225-1.
6
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.癌症治疗中靶向细胞周期蛋白依赖性激酶:蛋白水解靶向嵌合体和分子胶的进展
NPJ Precis Oncol. 2025 Jun 28;9(1):204. doi: 10.1038/s41698-025-00931-8.
7
Targeted protein degradation in Escherichia coli using CLIPPERs.利用CLIPPERs在大肠杆菌中进行靶向蛋白质降解
EMBO Rep. 2025 Jun 25. doi: 10.1038/s44319-025-00510-9.
8
Small Molecule-Induced Alterations of Protein Polyubiquitination Revealed by Mass-Spectrometric Ubiquitome Analysis.通过质谱泛素组分析揭示小分子诱导的蛋白质多聚泛素化改变
Angew Chem Int Ed Engl. 2025 Aug 4;64(32):e202508916. doi: 10.1002/anie.202508916. Epub 2025 Jun 26.
9
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells.在胰腺癌细胞中利用新型靶向BRD4的PROTAC劫持MDM2 E3连接酶
Chembiochem. 2025 May 2:e202500133. doi: 10.1002/cbic.202500133.
10
Histone Modifications: Potential Therapeutic Targets for Diabetic Retinopathy.组蛋白修饰:糖尿病视网膜病变的潜在治疗靶点
Biomolecules. 2025 Apr 12;15(4):575. doi: 10.3390/biom15040575.

本文引用的文献

1
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network.PIKES 分析揭示了降解物反应和 CRL4 网络关键调节机制。
Mol Cell. 2020 Mar 5;77(5):1092-1106.e9. doi: 10.1016/j.molcel.2019.12.013. Epub 2020 Jan 20.
2
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.结构基础:因斯德鲁单抗介导 RBM39 招募至 DCAF15 E3 连接酶复合物。
Nat Chem Biol. 2020 Jan;16(1):15-23. doi: 10.1038/s41589-019-0411-6. Epub 2019 Dec 9.
3
Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.RBM39 被磺胺类分子胶 E7820 招募到 DCAF15 的结构基础和动力学途径。
Structure. 2019 Nov 5;27(11):1625-1633.e3. doi: 10.1016/j.str.2019.10.005.
4
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.芳基磺酰胺通过募集至 CRL4-DCAF15 降解 RBM39 和 RBM23。
Cell Rep. 2019 Nov 5;29(6):1499-1510.e6. doi: 10.1016/j.celrep.2019.09.079.
5
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.结构互补促进 DCAF15 介导的 E7820 对 RBM39 的降解。
Nat Chem Biol. 2020 Jan;16(1):7-14. doi: 10.1038/s41589-019-0378-3. Epub 2019 Nov 4.
6
Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation.Cullin-RING 连接酶谱的可塑性影响配体诱导蛋白降解的敏感性。
Mol Cell. 2019 Aug 22;75(4):849-858.e8. doi: 10.1016/j.molcel.2019.07.013.
7
Cereblon modulators: Low molecular weight inducers of protein degradation.大脑酮体调节因子:蛋白质降解的低分子量诱导剂。
Drug Discov Today Technol. 2019 Apr;31:29-34. doi: 10.1016/j.ddtec.2019.02.004. Epub 2019 Mar 13.
8
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.通过 CRBN 定义噻唑并苯并二氮杂卓类似物靶向的人类 C2H2 锌指去泛素化酶。
Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat0572.
9
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.人类CDK12和CDK13,新千年的多任务CTD激酶。
Transcription. 2019 Apr;10(2):91-110. doi: 10.1080/21541264.2018.1535211. Epub 2018 Oct 22.
10
Efficient proximity labeling in living cells and organisms with TurboID.TurboID 实现活细胞和生物体内高效的邻近标记。
Nat Biotechnol. 2018 Oct;36(9):880-887. doi: 10.1038/nbt.4201. Epub 2018 Aug 20.